Summary
Edwards Lifesciences Corporation (EW) held its Annual Meeting of Stockholders on May 7, 2026, where key proposals related to executive compensation and corporate governance were voted upon. The most significant outcome for investors is the approval of the Amended and Restated Long-Term Stock Incentive Compensation Program. This program amendment includes an increase of 7,000,000 shares available for issuance, bringing the total to 341,500,000 shares. This expansion of the equity pool is crucial for future employee and executive compensation, potentially influencing long-term shareholder value through incentive alignment. Additionally, all director nominees were elected, and stockholders approved the advisory proposal on executive compensation and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm. The overwhelming approval of these proposals suggests continued confidence from shareholders in the company's leadership, compensation strategies, and financial oversight.
Key Highlights
- 1Stockholders approved the amendment and restatement of the Long-Term Stock Incentive Compensation Program.
- 2The Long-Term Stock Program now has an additional 7,000,000 shares available for issuance, increasing the total to 341,500,000 shares.
- 3All director nominees presented at the Annual Meeting were elected.
- 4The advisory proposal on executive compensation received stockholder approval.
- 5The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026 was ratified.
- 6The approval of the Amended and Restated Long-Term Stock Incentive Compensation Program passed with a significant majority of 'For' votes.